Inventaire - your friends and communities are your best library - Inventaire

The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.

author

Jen-Chung Ko

published in: Experimental Cell Research

date of publication: 2008-03-04

language: English

main subject: cytotoxicity

Cites articles 59

Date

Title

Authors

2007-08-01

Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer
2007-03-01

Induction of cell death, DNA strand breaks, and cell cycle arrest in DU145 human prostate carcinoma cell line by benzo[a]pyrene and benzo[a]pyrene-7,8-diol-9,10-epoxide
2006-12-01

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

Rafael Rosell
2006-07-01

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

Klaus Elenius
2006-08-01

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation

Dongyun Yang, Heinz-Josef Lenz
2006-06-13

PYK2 mediates anti-apoptotic AKT signaling in response to benzo[a]pyrene diol epoxide in mammary epithelial cells
2006-02-01

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

Christopher J Lord, Alan Ashworth
2005-12-01

Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists
2005-07-01

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

Yi-Long Wu, Xin-Yuan Guan
2005-11-01

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

Walter Kolch
2005-10-22

Attenuation of BPDE-induced p53 accumulation by TPA is associated with a decrease in stability and phosphorylation of p53 and downregulation of NFkappaB activation: role of p38 MAP kinase
2005-12-01

Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression

Jaffer Ajani, Scott Lippman
2005-01-01

Role of cell signaling in B[a]P-induced apoptosis: characterization of unspecific effects of cell signaling inhibitors and apoptotic effects of B[a]P metabolites.

Jørn Andreas Holme
2005-12-15

Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51
2005-04-01

Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
2004-05-20

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Daniel Haber, David C. Christiani
2004-06-04

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

Heidi Greulich, Stacey Gabriel, Matthew Meyerson, Pasi A Jänne, Titus J Boggon
2004-05-01

Gene expression profiles and genetic damage in benzo(a)pyrene diol epoxide-exposed TK6 cells

Chen-An Tsai
2004-10-01

Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
2003-12-22

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

American Society of Clinical Oncology, Andrew Turrisi
2003-02-01

BRCA2-dependent and independent formation of RAD51 nuclear foci.

Derek Davies, Stephen C. West
2003-04-03

ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway
2003-01-01

Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anti-cytotoxicity and anti-mutagenicity
2003-10-01

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

Roy S. Herbst, Mark G Kris
2003-05-01

RAD51 is involved in repair of damage associated with DNA replication in mammalian cells

Thomas Helleday
2002-01-01

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Chandra Belani, Corey J Langer
2002-05-01

Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia
2002-05-13

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor

Stanley J. Korsmeyer
2002-06-01

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

Grażyna Hoser, Agnieszka Bronisz, Janusz Błasiak, Ireneusz Majsterek, Tomasz Skórski
2001-03-01

The epidermal growth factor receptor as a target for cancer therapy
2001-03-01

Mammalian MAP kinase signalling cascades
2000

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy,Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

Article - wd:Q39996855

Welcome to Inventaire

the library of your friends and communities

you are offline